Sequential TransArterial Chemoembolization and Stereotactic RadioTherapy Followed by Durvalumab (MEDI4736) and Tremelimumab for Downstaging Hepatocellular Carcinoma for Hepatectomy
Latest Information Update: 08 Sep 2023
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Carcinoma; Liver cancer
- Focus Therapeutic Use
- 04 Sep 2023 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2024.
- 06 Jun 2023 Results (n=16) evaluating START-FIT activity using anti-PD-L1 and anti-CTLA-4 IO backbone, presented at the 59th Annual Meeting of the American Society of Clinical Oncology
- 10 Aug 2021 New trial record